New FDA Approved Drugs 2017

Following are the list of FDA Approved Drugs 2017 List For sale in United states.Information In This List Include; Date of Approval, Drug Name, its active drug And Uses.

FDA Approved Drugs 2017 List

• Jan-19-2017: Trulance (Active: Plecanatide)approved for the treatment of Chronic idiopathic constipation in Adult Patients.
• Feb-8-2017: Parsabiv (Active: Etelcalcetide) Approved for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis.
• Feb-9-2017: Emflaza (Active: deflazacort) Approved for the treatment of patients age 5 years and older with Duchenne muscular dystrophy (DMD).
• Feb-15-2017: Siliq Active: Brodalumab)To treat adults with moderate-to-severe plaque psoriasis.
• Feb-28-2017: Xermelo (Active: telotristat ethyl) To treat carcinoid syndrome diarrhea.
• March-13-2017: Kisqali (Active: ribociclib)To treat postmenopausal women with a type of advanced breast cancer.
• March-21-2017: Xadago (Active: safinamide)To treat Parkinson’s disease.
• March-23-2017: Bavencio (Active: avelumab)To treat metastatic Merkel cell carcinoma.
• March-23-2017: Symproic (Active: naldemedine)For the treatment of opioid-induced constipation.
• March-27-2017: Zejula ( Active: niraparib) For the maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers.
• March-28-2017: Dupixent (Active:Dupilumab)To treat adults with moderate-to-severe eczema (atopic dermatitis).

FDA Approved Drugs 2017

• March-28-2017: Ocrevuso (Active:Crelizumab)To treat patients with relapsing and primary progressive forms of multiple sclerosis.
• April-3-2017: Austedo (Active:Deutetrabenazine)For the treatment of chorea associated with Huntington’s disease.
• April-11-2017: Ingrezza (Active:valbenazine)To treat adults with tardive dyskinesia.
• April-27-2017:Brineura (Active:cerliponase alfa)To treat a specific form of Batten disease.
• April-28-2017: Alunbrig (Active:brigatinib)To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
• April-28-2017: Rydapt (Active:Midostaurin)To treat acute myeloid leukemia.
• April-28-2-17:Tymlos (Active: abaloparatide)To treat osteoporosis in postmenopausal women at high risk of fracture or those who have failed other therapies.
• May-1-2017:Imfinzi (Active:durvalumab) To treat patients with locally advanced or metastatic urothelial carcinoma.
• May-5-2017: Radicava (Active:edaravone)To treat patients with amyotrophic lateral sclerosis (ALS).
• May-22-2017: Kevzara (Active: Sarilumab)To treat adult rheumatoid arthritis.
• June-19-2017: Baxdela (Active: delafloxacin)To treat patients with acute bacterial skin infections.
• June-23-2017: Bevyxxa (Active: betrixaban)For the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness.
• July-13-2017: Tremfya (Active: guselkumab)For the treatment of adult patients with moderate-to-severe plaque psoriasis.
• July-17-2017: Nerlynx  (Active: neratinib maleate)To reduce the risk of breast cancer returning.
• July-18-2017: Vosevi (Active:Sofosbuvir, Velpetasvir,And Voxilaprevir)To treat adults with chronic hepatitis C virus.
• Aug-1-2017: Idhifa (Active:Enasidenib)To treat relapsed or refractory acute myeloid leukemia.
• Aug-3-2017: Mavyret (Active: glecaprevir and pibrentasvir) To treat adults with chronic hepatitis C virus .
• Aug-17-2017: Besponsa (Active: Inotuzumab ozogamicin) To treat adults with relapsed or refractory acute lymphoblastic leukemia.
• Aug-29-2017: Vabomere (Active:meropenem and vaborbactam) To treat adults with complicated urinary tract infections.
• Aug-29-2017:A drug benznidazole is approved by fda to treat children ages 2 to 12 years old with Chagas disease.
• Sep-14-2017: Aliqopa (Active: copanlisib) is approved to treat adults with relapsed follicular lymphoma.
• Sep-15-2017: Solosec ( Active: Secnidazole) Approved to treat bacterial vaginosis.
• Sep-28-2017: Verzinio (Active: abemaciclib) was approved To treat certain advanced or metastatic breast cancers.
• Oct-31-2017: Calquence (Active: acalabrutinib) To treat adults with mantle cell lymphoma.
• Nov-2-2017: Vyzulta ( latanoprostene bunod ophthalmic solution) To treat intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
• Nov-8-2017: Prevymis (letermovir)To prevent infection after bone marrow transplant.
• Nov-14-2017: Fesenra (benralizumab )For add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype .
• Nov-15-2017: Mapsevii (vestronidase alfa-vjbk) is used To treat pediatric and adult patients with an inherited metabolic condition called mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome.
• Nov-16-2017: Hemlibra: (emicizumab) is used To prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A who have developed antibodies called Factor VIII (FVIII) inhibitors.